Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.

Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).

Learning about Lirafugratinib: The First Highly Selective FGFR2 Inhibitor at #GI26 93% of tumors shrunk

Uncategorized

1 Posts 1 Posters 0 Views

W This user is from outside of this forum
W This user is from outside of this forum
Wafik S. El-Deiry, MD PhD FACP

wrote last edited by

#1

Learning about Lirafugratinib: The First Highly Selective FGFR2 Inhibitor at #GI26
93% of tumors shrunk
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute
1 Reply Last reply
1
0
I med-mastodon.com shared this topic